By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – GE Healthcare's Clarient will commercialize Biocept's blood test for circulating tumor cells under a deal announced today.
Lyle Arnold, Michael Dunn, Gilbert Omenn, Matthew Potter, David Bartel, Arthur Beaudet, George Church
Lyle Arnold, Michael Dunn join Biocept management team; HTG appoints John Lubniewski as chief business officer; Ora Hirsch Pescovitz joins Life Tech's board
The company's first test, a FISH-based assay targeting breast cancer, is planned for October and would represent its first product introduction in its 13-year history.
Rosetta Genomics, Hitachi, Biocept, Brigham and Women's Hospital, Tufts University
A new report offers ways for small, society publishers to transition to Plan S standards, ScienceInsider says.
A gas explosion sparked a fire at a Russian laboratory that stores dangerous pathogens, the Guardian reports.
Researchers turn to protein analysis to examine an ancient rhino sample, Smithsonian.com reports.
In PNAS this week: C2CD4A gene involved in insulin secretion, chromosome rearrangements in recurring S. aureus infections, and more.